3rd International AIDS Society Conference on HIV Pathogenesis and Treatment Rio de Janeiro - July 24 - 27, 2005

IS THE TREATMENT OF ACUTE HEPATITIS C IN HIV POSITIVE INDIVIDUALS EFFECTIVE?

IAS Conf HIV Pathog Treat 2005 Jul 24-27;3rd: Abstract No. TuPe1.1C10

Nelson M., Gilleece Y., Browne R., Asboe D., Atkins M., Mandalia S., Bower M., Gazzard B.
Chelsea & Westminster Hospital, London, United Kingdom

INTRODUCTION: To evaluate the effectiveness of treatment of acute hepatitis C infection in HIV-1 positive individuals.

METHODS: Patients diagnosed with acute hepatitis C by positive HCV antibody test had sequential HCV RNA levels measured at 0, 4, 12, 24, 32 and 48 weeks. If HCV RNA positive at 12 weeks patients were offered pegylated interferon α-2b 1.5µg/Kg/week + weight adjusted ribavirin for 24 weeks. Patients with increasing HCV RNA VL were offered treatment earlier.

RESULTS: 50 male homosexuals, mean age 37 yrs, were identified: 44 via newly abnormal LFT's, 4 from sexual contact with HCV positive partner and 2 at HIV seroconversion. 12 individuals became HCV RNA –ve spontaneously. This was significantly associated with a high baseline median CD4+ lymphocyte count (p=0.029), CD4+ lymphocyte count >500 (p=0.017) and lower HCV RNA VL (p=0.017). 27 patients accepted treatment, 16 (59%) of whom had a sustained virological response (SVR). This was associated with a higher peak mean ALT (p<0.001) but not with genotype.

CONCLUSIONS: SVR rates in HIV positive patients treated acutely for hepatitis C are lower than in HIV negative subjects. A high percentage of individuals seroconvert spontaneously.

Download PDF of this abstract.

050724
Clinical | TuPe1.1C10 | Mark Nelson
Hepatitis viruses

Copyright © 2005 - International AIDS Society (IAS). All information and content relating to the abstracts from the 3rd International AIDS Society Conference on HIV Pathogenesis and Treatment, such as text, graphics, logos, button icons, images, audio clips, and software is protected by copyright. Permission is hereby granted for the non-commercial use or reproduction of the information on this web site, provided that the use of such information is accompanied by an acknowledgement that IAS is the source of the information and the name of the author of the article.

AEGiS is made possible through unrestricted funding from Boehringer Ingelheim, Bridgestone/Firestone Charitable Trust, Bristol-Myers Squibb Company, Elton John AIDS Foundation, the National Library of Medicine, and donations from users like you. Always watch for outdated information. This article first appeared in 2005. This material is designed to support, not replace, the relationship that exists between you and your doctor.

AEGiS presents published material, reprinted with permission and neither endorses nor opposes any material. All information contained on this website, including information relating to health conditions, products, and treatments, is for informational purposes only. It is often presented in summary or aggregate form. It is not meant to be a substitute for the advice provided by your own physician or other medical professionals. Always discuss treatment options with a doctor who specializes in treating HIV.

Copyright ©1980, 2005. AEGiS. All materials appearing on AEGiS are protected by copyright as a collective work or compilation under U.S. copyright and other laws and are the property of AEGiS, or the party credited as the provider of the content. Permission is hereby granted for the non-commercial use or reproduction of the information herein, provided that the use of such information is accompanied by an acknowledgement that IAS is the source of the information and the name of the author of the article.